| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Mofsen, J Balte. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clinical therapeutics. vol 23. issue 10. 2002-04-03. PMID:11726006. |
although the efficacy of clozapine in the management of treatment-resistant schizophrenia has been well established, reports of relapse after conversion to a generic formulation are becoming more common. |
2002-04-03 |
2023-08-12 |
Not clear |
| L Chalasani, R Kant, K N Chengapp. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 46. issue 10. 2002-03-20. PMID:11816319. |
clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. |
2002-03-20 |
2023-08-12 |
Not clear |
| L Chalasani, R Kant, K N Chengapp. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 46. issue 10. 2002-03-20. PMID:11816319. |
to evaluate the impact of clozapine on aggressive behaviour and clinical outcomes in children and adolescents with schizophrenia or schizoaffective disorder. |
2002-03-20 |
2023-08-12 |
Not clear |
| David C Henderso. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS drugs. vol 16. issue 2. 2002-03-19. PMID:11825099. |
while definitive studies have yet to be reported, mounting evidence suggests that the atypical antipsychotic agents, particularly clozapine and olanzapine, may significantly impair glucose metabolism and increase the risk of diabetes in patients with schizophrenia. |
2002-03-19 |
2023-08-12 |
Not clear |
| V C Kirpekar, S M Deshpande, P P Josh. Reversible myocarditis in a patient receiving clozapine. Indian heart journal. vol 53. issue 6. 2002-03-14. PMID:11838936. |
we report the case of a 2 6-year-old patient who developed reversible myocarditis during treatment with clozapine for chronic resistant schizophrenia. |
2002-03-14 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, M G Scordo, M Ancione, A Madia, A Levit. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Therapeutic drug monitoring. vol 23. issue 6. 2002-03-07. PMID:11802103. |
the effect of reboxetine on steady-state plasma concentrations of the atypical antipsychotics clozapine and risperidone was studied in 14 patients with schizophrenia or schizoaffective disorder with associated depressive symptoms. |
2002-03-07 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
the authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| Theodore T Kolivakis, Howard C Margolese, Linda Beauclair, Guy Chouinar. Clozapine for first-episode schizophrenia. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823283. |
clozapine for first-episode schizophrenia. |
2002-03-06 |
2023-08-12 |
Not clear |
| P I Oh, M Iskedjian, A Addis, K Lanctôt, T R Einarso. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 8. issue 4. 2002-02-28. PMID:11743592. |
pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. |
2002-02-28 |
2023-08-12 |
Not clear |
| P I Oh, M Iskedjian, A Addis, K Lanctôt, T R Einarso. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 8. issue 4. 2002-02-28. PMID:11743592. |
clozapine appears to be a very cost effective therapy in patients with treatment-resistant schizophrenia compared with haloperidol and chlorpromazine. |
2002-02-28 |
2023-08-12 |
Not clear |
| Malcolm Peet, David F Horrobi. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of psychiatric research. vol 36. issue 1. 2002-02-27. PMID:11755456. |
115 patients with dsm-iv-defined schizophrenia were studied, 31 on clozapine, 48 on new atypical drugs and 36 on typical antipsychotics. |
2002-02-27 |
2023-08-12 |
Not clear |
| A Mechri, J Micallef, O Blin, M Saoud, J Daléry, L Gah. [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses]. Therapie. vol 56. issue 5. 2002-02-27. PMID:11806303. |
in healthy subjects, a sub-anaesthetic single dose of lorazepam, typical neuroleptics, such as haloperidol, and atypical neuroleptics, such as clozapine and olanzapine, failed to block ketamine-induced positive and negative symptoms resembling schizophrenia. |
2002-02-27 |
2023-08-12 |
human |
| M Bourin, B Guitton, E Dailly, P Hery, P Jollie. A follow-up study of a population of schizophrenic patients treated with clozapine. Progress in neuro-psychopharmacology & biological psychiatry. vol 25. issue 8. 2002-02-26. PMID:11642649. |
its efficacy for the treatment of the symptoms of schizophrenia is known, but the use of clozapine is limited to treatment-resistant schizophrenic patients as it induces agranulocytosis with a higher incidence than that of other neuroleptic drugs. |
2002-02-26 |
2023-08-12 |
human |
| K N R Chengappa, J Vasile, J Levine, R Ulrich, R Baker, A Gopalani, N Schoole. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia research. vol 53. issue 1-2. 2002-02-22. PMID:11728832. |
over a three year period, 137 subjects with schizophrenia or schizoaffective disorder received clozapine, of whom nearly 50% (n=69) experienced seclusion or restraint. |
2002-02-22 |
2023-08-12 |
human |
| A Wirz-Justice, H J Haug, C Cajoche. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophrenia bulletin. vol 27. issue 3. 2002-02-07. PMID:11596850. |
the circadian rest-activity cycle of schizophrenia patients stabilized for more than a year on monotherapy with a "classical" neuroleptic (haloperidol, flupentixol) or with the atypical neuroleptic clozapine was documented by continuous activity monitoring for 3-7 weeks. |
2002-02-07 |
2023-08-12 |
Not clear |
| B A Johansson, H Jarbin, J Lundgre. [Difficulties in the treatment of psychosis in young patients with epilepsy]. Lakartidningen. vol 98. issue 49. 2002-02-01. PMID:11783054. |
we will argue for considering clozapine early in treatment if other antipsychotics have failed based on two cases; these patients both developed epilepsy in early childhood and schizophrenia in mid adolescence. |
2002-02-01 |
2023-08-12 |
Not clear |
| S G Potkin, K Fleming, Y Jin, B Gulasekara. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of clinical psychopharmacology. vol 21. issue 5. 2002-01-24. PMID:11593072. |
neurocognition and clinical symptomatology were evaluated in 27 patients with schizophrenia during a double-blind, placebo-controlled, cross-over study involving clozapine, an atypical antipsychotic agent, and haloperidol, a conventional neuroleptic. |
2002-01-24 |
2023-08-12 |
Not clear |
| D C Goff, L Leahy, I Berman, T Posever, L Herz, A C Leon, S A Johnson, G Lync. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 5. 2002-01-24. PMID:11593073. |
a placebo-controlled pilot study of the ampakine cx516 added to clozapine in schizophrenia. |
2002-01-24 |
2023-08-12 |
Not clear |
| D A Revick. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Current opinion in investigational drugs (London, England : 2000). vol 2. issue 1. 2002-01-22. PMID:11527002. |
the research evidence suggests that clozapine is a cost-effective treatment for neuroleptic refractory schizophrenia. |
2002-01-22 |
2023-08-12 |
Not clear |